Derek Archila
Stock Analyst at Wells Fargo
(4.08)
# 532
Out of 5,051 analysts
194
Total ratings
52.8%
Success rate
11.87%
Average return
Main Sectors:
Stocks Rated by Derek Archila
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLNO Soleno Therapeutics | Maintains: Overweight | $123 → $106 | $45.62 | +132.35% | 2 | Nov 5, 2025 | |
| ANAB AnaptysBio | Maintains: Overweight | $51 → $81 | $36.22 | +123.63% | 4 | Nov 5, 2025 | |
| KYTX Kyverna Therapeutics | Maintains: Overweight | $27 → $31 | $6.51 | +376.19% | 3 | Oct 30, 2025 | |
| INCY Incyte | Maintains: Overweight | $89 → $97 | $103.56 | -6.33% | 10 | Oct 29, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $22 → $21 | $12.12 | +73.27% | 6 | Oct 23, 2025 | |
| EXEL Exelixis | Maintains: Equal-Weight | $36 → $30 | $39.24 | -23.55% | 4 | Oct 21, 2025 | |
| KZR Kezar Life Sciences | Maintains: Equal-Weight | $7 → $5 | $6.10 | -18.03% | 12 | Oct 17, 2025 | |
| APLS Apellis Pharmaceuticals | Upgrades: Overweight | $29 → $32 | $20.29 | +57.71% | 13 | Oct 15, 2025 | |
| CCCC C4 Therapeutics | Maintains: Overweight | $5 → $10 | $2.32 | +331.03% | 6 | Sep 23, 2025 | |
| ATYR aTyr Pharma | Downgrades: Equal-Weight | $25 → $1 | $0.79 | +26.58% | 3 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $38 | $23.43 | +62.19% | 4 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $3 | $1.02 | +194.12% | 1 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $2 | $2.50 | -20.00% | 11 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $289 → $295 | $204.28 | +44.41% | 14 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $6 → $5 | $1.32 | +278.79% | 5 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $27 → $26 | $22.82 | +13.94% | 2 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $19 → $16 | $9.42 | +69.85% | 7 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $741 → $756 | $829.15 | -8.82% | 12 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $4.57 | +272.40% | 1 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $91 → $129 | $98.95 | +30.37% | 6 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $57 → $53 | $58.25 | -9.01% | 8 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $18 | $19.11 | -5.81% | 4 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $10 | $11.98 | -16.53% | 5 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $15 | $2.34 | +541.03% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $14 | $18.17 | -22.97% | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $45 | $23.85 | +88.68% | 9 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $11 | $8.50 | +29.41% | 4 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $3.04 | +228.95% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $37 → $20 | $2.86 | +599.30% | 7 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $4.07 | +342.26% | 1 | Aug 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $4.03 | - | 1 | Jul 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $298 → $193 | $30.31 | +536.75% | 1 | Jul 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $61 → $41 | $64.84 | -36.77% | 1 | Apr 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $480 → $160 | $15.44 | +936.27% | 3 | Mar 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $180 → $60 | $14.64 | +309.84% | 3 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $29 | $4.47 | +548.77% | 4 | Dec 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $50 | $1.08 | +4,529.63% | 2 | Jun 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $51 | $19.10 | +167.02% | 1 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $88 | $16.18 | +443.88% | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $22.18 | - | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $24.04 | - | 2 | Aug 3, 2017 |
Soleno Therapeutics
Nov 5, 2025
Maintains: Overweight
Price Target: $123 → $106
Current: $45.62
Upside: +132.35%
AnaptysBio
Nov 5, 2025
Maintains: Overweight
Price Target: $51 → $81
Current: $36.22
Upside: +123.63%
Kyverna Therapeutics
Oct 30, 2025
Maintains: Overweight
Price Target: $27 → $31
Current: $6.51
Upside: +376.19%
Incyte
Oct 29, 2025
Maintains: Overweight
Price Target: $89 → $97
Current: $103.56
Upside: -6.33%
Nurix Therapeutics
Oct 23, 2025
Maintains: Overweight
Price Target: $22 → $21
Current: $12.12
Upside: +73.27%
Exelixis
Oct 21, 2025
Maintains: Equal-Weight
Price Target: $36 → $30
Current: $39.24
Upside: -23.55%
Kezar Life Sciences
Oct 17, 2025
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $6.10
Upside: -18.03%
Apellis Pharmaceuticals
Oct 15, 2025
Upgrades: Overweight
Price Target: $29 → $32
Current: $20.29
Upside: +57.71%
C4 Therapeutics
Sep 23, 2025
Maintains: Overweight
Price Target: $5 → $10
Current: $2.32
Upside: +331.03%
aTyr Pharma
Sep 16, 2025
Downgrades: Equal-Weight
Price Target: $25 → $1
Current: $0.79
Upside: +26.58%
Aug 20, 2025
Maintains: Overweight
Price Target: $44 → $38
Current: $23.43
Upside: +62.19%
Aug 12, 2025
Maintains: Equal-Weight
Price Target: $4 → $3
Current: $1.02
Upside: +194.12%
Aug 8, 2025
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $2.50
Upside: -20.00%
Aug 8, 2025
Maintains: Overweight
Price Target: $289 → $295
Current: $204.28
Upside: +44.41%
Aug 7, 2025
Maintains: Equal-Weight
Price Target: $6 → $5
Current: $1.32
Upside: +278.79%
Aug 7, 2025
Maintains: Equal-Weight
Price Target: $27 → $26
Current: $22.82
Upside: +13.94%
Aug 7, 2025
Maintains: Overweight
Price Target: $19 → $16
Current: $9.42
Upside: +69.85%
Jul 31, 2025
Maintains: Overweight
Price Target: $741 → $756
Current: $829.15
Upside: -8.82%
Jul 25, 2025
Initiates: Overweight
Price Target: $17
Current: $4.57
Upside: +272.40%
Jul 10, 2025
Maintains: Overweight
Price Target: $91 → $129
Current: $98.95
Upside: +30.37%
Jun 26, 2025
Maintains: Overweight
Price Target: $57 → $53
Current: $58.25
Upside: -9.01%
May 16, 2025
Maintains: Equal-Weight
Price Target: $11 → $18
Current: $19.11
Upside: -5.81%
Mar 21, 2025
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $11.98
Upside: -16.53%
Mar 12, 2025
Maintains: Equal-Weight
Price Target: $16 → $15
Current: $2.34
Upside: +541.03%
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $12 → $14
Current: $18.17
Upside: -22.97%
Dec 19, 2024
Maintains: Overweight
Price Target: $47 → $45
Current: $23.85
Upside: +88.68%
Aug 12, 2024
Maintains: Overweight
Price Target: $16 → $11
Current: $8.50
Upside: +29.41%
May 15, 2024
Maintains: Overweight
Price Target: $12 → $10
Current: $3.04
Upside: +228.95%
May 5, 2021
Downgrades: Hold
Price Target: $37 → $20
Current: $2.86
Upside: +599.30%
Aug 4, 2020
Initiates: Buy
Price Target: $18
Current: $4.07
Upside: +342.26%
Jul 23, 2020
Upgrades: Buy
Price Target: n/a
Current: $4.03
Upside: -
Jul 10, 2020
Downgrades: Hold
Price Target: $298 → $193
Current: $30.31
Upside: +536.75%
Apr 15, 2020
Reiterates: Buy
Price Target: $61 → $41
Current: $64.84
Upside: -36.77%
Mar 31, 2020
Maintains: Hold
Price Target: $480 → $160
Current: $15.44
Upside: +936.27%
Mar 17, 2020
Downgrades: Hold
Price Target: $180 → $60
Current: $14.64
Upside: +309.84%
Dec 11, 2018
Downgrades: Perform
Price Target: $29
Current: $4.47
Upside: +548.77%
Jun 22, 2018
Maintains: Outperform
Price Target: $34 → $50
Current: $1.08
Upside: +4,529.63%
Nov 15, 2017
Maintains: Outperform
Price Target: $32 → $51
Current: $19.10
Upside: +167.02%
Sep 7, 2017
Initiates: Outperform
Price Target: $88
Current: $16.18
Upside: +443.88%
Sep 7, 2017
Initiates: Market Perform
Price Target: n/a
Current: $22.18
Upside: -
Aug 3, 2017
Downgrades: Perform
Price Target: n/a
Current: $24.04
Upside: -